152 related articles for article (PubMed ID: 34079223)
21. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer.
Huq F; Yu JQ; Beale P; Chan C; Arzuman L; Nessa MU; Mazumder ME
Anticancer Res; 2014 Jan; 34(1):541-5. PubMed ID: 24403514
[TBL] [Abstract][Full Text] [Related]
22. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
23. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
24. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
26. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2011 Nov; 31(11):3789-97. PubMed ID: 22110201
[TBL] [Abstract][Full Text] [Related]
27. Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells.
Shin SY; Jung H; Ahn S; Hwang D; Yoon H; Hyun J; Yong Y; Cho HJ; Koh D; Lee YH; Lim Y
Bioorg Med Chem; 2014 Mar; 22(6):1809-20. PubMed ID: 24565968
[TBL] [Abstract][Full Text] [Related]
28. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
29. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
Bodo J; Chovancova J; Hunakova L; Sedlak J
Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, characterisation, activities, cell uptake and DNA binding of [[trans-PtCl(NH3)2] [mu-(H2N(CH2)6NH2)] [trans-PdCl(NH3)2](NO3)Cl.
Huq F; Daghriri H; Yu JQ; Tayyem H; Beale P; Zhang M
Eur J Med Chem; 2004 Nov; 39(11):947-58. PubMed ID: 15501544
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines.
Arzuman L; Beale P; Yu JQ; Huq F
Anticancer Res; 2016 Jun; 36(6):2809-18. PubMed ID: 27272792
[TBL] [Abstract][Full Text] [Related]
33. Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines.
Alshehri A; Beale P; Yu JQ; Huq F
Anticancer Res; 2010 Nov; 30(11):4547-53. PubMed ID: 21115904
[TBL] [Abstract][Full Text] [Related]
34. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
35. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
36. Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Nov; 32(11):4843-50. PubMed ID: 23155250
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913
[TBL] [Abstract][Full Text] [Related]
38. The effect of sodium butyrate and cisplatin on expression of EMT markers.
Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M
PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577
[TBL] [Abstract][Full Text] [Related]
39. Synergism from combination of cisplatin and multicentred platinums coded as DH6Cl and TH1 in the human ovarian tumour models.
Alshehri A; Beale P; Yu JQ; Huq F
Med Chem; 2011 Nov; 7(6):593-8. PubMed ID: 22313299
[TBL] [Abstract][Full Text] [Related]
40. Nitric oxide affects cisplatin cytotoxicity oppositely in A2780 and A2780-CDDP cells via the connexin32/gap junction.
Fan L; Zheng N; Peng F; Zhao Z; Fan D; Cai S; Tao L; Wang Q
Cancer Sci; 2020 Aug; 111(8):2779-2788. PubMed ID: 32342615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
